Combination of GQD, a probioitic, with anti-PD1 therapy led to alteration of the gut microbiome and metabolome along with increased immunotherapy efficacy, systemic and tumor CD8 T cells as well as IFN-γ production. This evidence concerns the gene CD8A and neoplasm.